CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two ...

Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.

In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...

A therapy that has revolutionised how we treat blood and skin cancers could become even more effective. Making cancer cells stiffer bolstered the effects of immunotherapy, when the immune system is ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most ...

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for more than 85% of all cancers. Columbia University ...